Log in to save to my catalogue

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2273766258

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

About this item

Full title

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

Publisher

United States: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2019-08, Vol.381 (7), p.626-636

Language

English

Formats

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

In long-term follow-up of more than 500 patients with melanoma containing a
BRAF
V600E or V600K mutation, a combination of dabrafenib plus trametinib was associated with progression-free survival in 19% of the patients and overall survival in 34% at 5 years. A complete response to dabrafenib plus trametinib was the strongest predictor of long...

Alternative Titles

Full title

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2273766258

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2273766258

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1904059

How to access this item